INNOGENE Co., Ltd.
KKRX:3448601,476.00
KRW
+42.00
(+2.93%)
ISIN
KR7344860002
Return %
Stock
S&P 500
1Y
-8.32
14.39
3Y
-44.20
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Gwang-Hoon Lee
- Full Time Employees
- 58
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seoul South Korea
- IPO Date
- Feb 20, 2023
- Website
- innogene.com
- Similar Companies
- Business
- INNOGENE Co., Ltd. is a South Korea-based biotechnology and cosmeceutical company specializing in anti-aging, hair loss therapeutics, scalp care, and medical skincare solutions. Founded in 2005 and headquartered in Seoul, South Korea, the company operates across the bio-cosmetics, medical aesthetic device, and healthcare industries, delivering an integrated total solution platform encompassing diagnosis, clinical treatment, home maintenance, and post-procedure care. The company develops, manufactures, and distributes products across four core proprietary brand lines: BallVic, a specialized hair loss and scalp care line comprising therapeutic shampoos, scalp tonics, intensive ampoules, and targeted condition regimens including BallVic S for male-pattern hair loss, BallVic W for female thinning hair, and BallVic SEBO for seborrheic scalp conditions; Re:Cellby, a hospital-exclusive derma-cosmetic brand focused on post-dermatological procedure skin soothing and skin barrier regeneration; Dr.Medicean, a specialized cosmeceutical brand addressing chronic troubled, atopic, and irritated skin conditions; and Follicution, a clinical-grade scalp meso-solution and professional clinic treatment line. In addition to topical cosmeceuticals, INNOGENE supplies optical scalp diagnostic systems, hair and scalp care equipment, mobile scalp condition tracking applications, and dietary health supplements formulated for hair and skin vitality. The company operates a dual-channel business model, serving a B2B network of over 4,000 domestic dermatologists, plastic surgery clinics, and hospitals, alongside a B2C retail presence spanning major duty-free retail networks and online commerce platforms. Geographically, INNOGENE conducts international distribution across more than 20 countries, including China, Singapore, Malaysia, and other regional Asian markets. In recent corporate developments, INNOGENE listed its shares on the KOSDAQ market (KRX: 344860) in February 2023, establishing access to public capital markets. In recent operational and strategic changes, the company secured an exclusive overseas supply agreement to expand international distribution, broadened its consumer sales channels through major online duty-free stores including Lotte and Shilla, and executed a third-party allotment capital increase in 2026 to finance operational expansion and digital marketing initiatives. Furthermore, INNOGENE is strategically advancing its development of big-data-driven personalized scalp analysis diagnostics and expanded functional care foods to scale its comprehensive anti-aging ecosystem.